Relying on our advanced molecular biology platform and experienced nucleic acid R&D and production team, CD Formulation offers high-quality, customized, and large-scale nucleic acid custom synthesis services. Our platform not only provides standard, unmodified nucleic acids but also produces complex nucleic acids that require multiple modifications and precisely matched nucleic acid drugs (siRNA, Aptamer, ASO, etc.).
Nucleic acid drugs are drugs with specific base sequences, including mini-nucleic acid drugs and mRNA vaccines. Nucleic acid products are now widely used in basic research as well as in the clinical diagnosis and treatment of diseases such as tumors, infectious diseases, blood diseases and neurodegenerative diseases. Compared with other drugs, nucleic acid drugs do not require complex protein modification, the preparation process is relatively simple in the production stage, and large-scale mammalian cell fermentation and protein purification are not required, which has the advantages of rich candidate targets, short R&D cycle, long-lasting efficacy, and a high success rate in clinical development. Nucleic acid drugs are of great market potential, no matter from the perspective of basic research and development to industrial application and pharmaceutical process improvement, its application prospect is very broad, which requires researchers to continuously develop and study.
CD Formulation has a powerful nucleic acid custom synthesis platform and a team of experienced nucleic acid experts capable of synthesizing nucleic acids with various sequences and lengths. Moreover, we provide a variety of nucleic acid modification services, including base modification, to improve the stability and structural flexibility of the nucleic acids.
CD Formulation provides comprehensive and specialized quality control analysis to ensure the quality, safety and efficacy of nucleic acid drug products, and is an integral part of the overall development solution.
Fig.1 Our Solutions for Nucleic Acid Customization. (CD Formulation)
Items | Technologies | Descriptions |
---|---|---|
Nucleic Acid Sequence Analysis | Capillary Electrophoresis Mass Spectrometry Bioinformatics Analysis Enzyme Sequencing High-throughput Sequencing |
Capillary electrophoresis, mass spectrometry and other techniques are used to accurately determine nucleic acid sequences to ensure that they are consistent with the intended design. |
Physicochemical Analysis | UV-Vis Absorption Spectroscopy Dynamic Light Scattering (DLS) Thermal Analysis Spectroscopy Chromatography |
Determination of basic physicochemical parameters such as concentration, pH, ionic strength, melting point, etc. |
Bioactivity Analysis | Enzyme Activity Assay Gene Expression Analysis Proteomics Analysis |
Evaluate the targeting and biological activity of nucleic acid drugs using cellular assays or animal models. |
Stability Analysis | Accelerated Stability Assay Light Stability Assay Thermodynamic Analysis pH Stability Analysis Chemical Stability Analysis Microbiological Testing |
Examine the changes in physicochemical and biological properties of nucleic acid drugs over time under various conditions (such as temperature, light, pH, etc.). |
Impurity Analysis | Capillary Electrophoresis (CE) Gel Electrophoresis Liquid Chromatography Mass Spectrometry (MS) Nuclear Magnetic Resonance (NMR) |
Detects structural impurities such as nucleic acid strand breaks, mismatched bases, chemical modifications, etc. |
Safety Analysis | Cytotoxicity Determination Genotoxicity Analysis Immunogenicity Assay Bioactivity Analysis Pharmacokinetic Analysis Toxicology Studies |
Evaluate safety indicators such as cytotoxicity, immunogenicity, and genotoxicity. |
Product types: ASO, siRNA, Aptamer, mRNA, etc.
Synthesized amount: from microgram to gram.
Modification types: there are more than 200 types of modifications available, and the range of modification options is expanding based on customers' requirements. Customized modification services are offered for reagents provided by customers.
Phase reports: sequence design results, synthetic sequence QC report, modification product QC report, experimental methodology development program, experimental test report, screening and validation report, and pharmacodynamic study report.
Technology: Preparation of nucleic acids by solid-phase synthesis technology
Journal: Bioorganic Chemistry
IF: 4.5
Published: 2023
Results:
The authors state that solid-phase synthesis is the preferred method for manufacturing oligonucleotide in quantities ranging from a few micrograms for research to several kilograms for therapeutic or commercial use. However, for large-scale oligonucleotide production, scale-up and hazardous waste generation poses challenges, necessitating the investigation of alternative synthesis techniques. In this study, the authors review the current state of development, advantages, and difficulties of recently reported alternatives to support based on controlled pore glass, and discuss the importance of support selection for solving problems that arise during oligonucleotide synthesis.
Fig. 2 Chemical methods for nucleic acids synthesis. (Jolanta Brzezinska. et al., 2023)
CD Formulation, as a professional nucleic acid drug developer, can not only customize ASOs, siRNAs, mRNAs, etc., but also provide nucleic acid modification services for customers. If you are interested in our service, please feel free to contact us, we will provide the most efficient solution for your research.
References